
OS Therapies Inc. (NYSE:OSTX), a clinical-stage cancer immunotherapy and antibody drug conjugate biotechnology company, released survival data on Friday from the Phase 2b trial of its off-the-shelf immunotherapy candidate, OST-HER2, for pulmonary metastatic osteosarcoma, an aggressive type of bone cancer.
The data showed statistically significant positive final 2-year overall survival data in the prevention or delay of recurrent, fully resected, pulmonary metastatic osteosarcoma.